Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Conditions:   Human Papillomavirus Infection;   Stage I Oral Cavity Squamous Cell Carcinoma;   Stage I Oropharyngeal Squamous Cell Carcinoma;   Stage II Oral Cavity Squamous Cell Carcinoma;   Stage II Oropharyngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Procedure: Therapeutic Conventional Surgery
Sponsors:   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
Not yet recruiting - verified July 2016

from #ENT via xlomafota13 on Inoreader http://ift.tt/29I1ldg
via IFTTT